MPC 2130

Drug Profile

MPC 2130

Alternative Names: MPC-2130

Latest Information Update: 26 Nov 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class
  • Mechanism of Action Apoptosis stimulants; Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Haematological malignancies

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 16 Sep 2010 Discontinued - Phase-I for Cancer in USA (IV)
  • 16 Sep 2010 Discontinued - Phase-I for Haematological malignancies in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top